INTRODUCTION

Infective endocarditis (IE), primarily caused by
Gram-positive bacteria, is associated with a high rate of morbidity and mortality, which represents a large burden to the healthcare system [1] . Hospitalizations due to IE rose from 25,511 to 38,976 between 1998 and 2009 in the United States, with increase in serious neurologic and cardiac complications [2] . Mortality associated with IE ranges between 15% and 20% [2] [3] [4] [5] .
Although IE is associated with a variety of microorganisms, staphylococci, streptococci and enterococci account for the majority of cases [6] . Staphylococcus aureus is the most commonly detected causative agent [4, 5] . A cohort study showed that among 2781 patients with IE, the most common pathogens were S. aureus (31%), viridans group streptococci (17%), enterococci (10%), coagulase-negative staphylococci (11%), Streptococcus bovis (6%), and other streptococci (6%) [5] .
Methicillin-resistant S. aureus (MRSA) has emerged as a common pathogen in both healthcare and community-acquired infections [7, 8] . Community-acquired MRSA has been found to be particularly responsible for causing IE in patients with human immunodeficiency virus [9] . Another multinational study reported an increase in the relative proportion of both hospital-and community-onset of MRSA bloodstream infections [10] . MRSA infections, including IE, are associated with higher levels of mortality compared to methicillin-susceptible S. aureus (MSSA) [11, 12] . The resistance of pathogens to commonly used antibiotics is one of the major public health problems, and the successful treatment of IE remains challenging. Patients with IE require an aggressive treatment approach with effective antibiotics or a combination of effective antibiotics and surgery [13] [14] [15] .
Daptomycin is a bactericidal, cyclic lipopeptide that is active against Grampositive bacteria. The mechanism of action involves binding (in the presence of calcium ions) to bacterial membranes of both growing and stationary phase cells causing depolarization and leading to a rapid inhibition of protein, deoxyribonucleic acid and ribonucleic acid synthesis. This results in bacterial cell death with negligible cell lysis [16] .
Daptomycin is associated with concentrationdependent activity, hence a high dose of daptomycin has the ability to penetrate bacterial biofilm and may help to prevent the emergence of bacterial resistance [1] .
Daptomycin is approved for the treatment of complicated skin and skin-structure infections caused by Gram-positive pathogens, bacteremia and right-sided IE caused by S. aureus [17, 18] .
Infective endocarditis can affect the right side (RIE), left side (LIE) or both sides (BRLIE) of the heart. Reports from earlier studies suggest that daptomycin can be useful in the treatment of both LIE as well as RIE [18] [19] [20] [21] 
METHODS
Patients and Data Collection
This analysis includes patients enrolled in EU-CORE, a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome data on patients who had received at least one dose of daptomycin for the treatment of a serious Gram-positive bacterial infection. The protocol was approved by the health authority and the Institutional Review Board (IRB) or Ethics Committee (EC) in each country and written informed consent was obtained according to the requirements of the IRB or EC and/or the local data privacy regulations. Patients who might have received daptomycin as part of a controlled clinical trial were excluded from retrospective collection of data. Details of the EU-CORE registry have been published previously [11, [22] [23] [24] .
The data from the registry were collected using standardized case report forms for patients with IE who had received at least one 
Clinical Outcomes
In this retrospective study, data from 610 patients with IE as well as 185 patients with with daptomycin doses C8 mg/kg/day was higher compared with lower doses. There was a trend towards higher rates of success as daptomycin doses increased (Table 4) 
Proportion of patients (%)
Non-evaluable Failure Success Fig. 1 Clinical outcomes in patients with infective endocarditis. BRLIE both right-and left-sided infective endocarditis, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis remained relapse free at the end of the 2-year follow-up period (Fig. 2) .
Safety
An overview of AEs is presented in Table 5 . Overall, 5 (3.4%), 30 (7.2%) and 2 (4.3%) patients with RIE, LIE and BRLIE discontinued daptomycin therapy due to AEs, respectively. The numbers of reported AEs which were related to daptomycin were low: 2 (1.3%) in patients with RIE, 18 (4.3%) in patients with LIE, and 1 (2.1%) patients with BRLIE. Among
AEs reported as related to daptomycin, creatine phosphokinase (CPK) elevation was observed in 2 (1.3%), 8 (1.9%) and 1 (2.1%) patients, with RIE, LIE and BRLIE, respectively. Two patients (LIE) developed eosinophilic pneumonia. Death was reported in 5 (3.4%), 53 (12.8%) and 7 (14.9%) patients with RIE, LIE and BRLIE, respectively; none of the SAEs associated with deaths were considered to be related to daptomycin. 
AE adverse event, BRLIE both right-and left-sided infective endocarditis, CPK creatine phosphokinase, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis, SAE serious AE mortality have not decreased in the past 30 years. Although there were major advances in diagnostic and therapeutic procedures, the disease still carries a poor prognosis and a high mortality [26] . The present retrospective analysis from the EU-CORE patient registry provides valuable information on real-life experience of patients with IE who were treated with daptomycin across multiple centers from 18 countries, which may not otherwise be apparent from a randomized clinical trial.
Data from this analysis demonstrate that daptomycin was successful for the treatment of patients with IE caused by Gram-positive bacteria, including MRSA. This finding is consistent with the earlier published reports [11, 27] . Overall, clinical success rates were high, demonstrating effective use of daptomycin to treat IE. In this analysis, there was a trend towards higher success rate with higher daptomycin doses C8 mg/kg/day (maximum dose was 12 mg/kg/day) compared with lower doses.
This was consistent with a previous report [21] . Hence, the use of higher doses of There was a higher proportion of enterococcal infection in patients with LIE than in RIE and BRLIE. Also, there was a broader range of streptococcal infections in LIE than in RIE or BRLIE. In this study, MSSA was more commonly isolated than MRSA from patients with IE.
Patients with IE who had complicated MSSA and MRSA infections and received daptomycin therapy had high success rates. These results are consistent with the findings from an earlier in vitro study on IE model which showed that daptomycin had better bactericidal activity against the biofilm-forming MRSA compared with vancomycin [29] . Data from a prospective cohort study reported that the mortality of patients with IE infections caused by MRSA isolates was high with vancomycin minimum inhibitory concentration of 2 mg/L (determined by Etest) [30] . Daptomycin at higher doses may be considered as first-line therapy to manage both MSSA and MRSA infections in patients with IE, which was also mentioned in an earlier published report [31] . In an in vitro study, it was observed that daptomycin in combination with 
